Drugs
The T-DM1 data presented Saturday "are quite the validating statement for our technology," said ImmunoGen CEO Dan Janius. "A year from now, we could have T-DM1 on the market for an indication where there is no approved therapy today."
Roche is conducting already conducting a separate phase III study testing T-DM1 head-to-head against Glaxo's Tykerb in second-line breast cancer patients. A phase II study of T-DM1 compared to Herceptin in first-line breast cancer will have data ready for presentation at an upcoming medical meeting. ImmunoGen shares closed Friday at $8.77.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 14.60 |
Oil *
98.16
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
1.21 |
10 Yr
1.46%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-7.65%
|
Data delayed 20 minutes |
Connect with TheStreet